Ozempic was North Carolina's second most expensive Medicare Part D drug in 2023 at $407 million. Medicare's negotiated price starts in 2027. Here is what that means for you.
Ranked 43rd in prescriptions. But Ozempic is North Carolina's second most expensive Medicare drug, and it's still climbing.
Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist for Type 2 diabetes. It lowers blood sugar and has demonstrated cardiovascular benefits. Medicare Part D covers it for diabetes, not for weight loss alone. North Carolina's diabetes rate is above the national average, and that disease burden drives significant GLP-1 volume.
Novo Nordisk manufactures Ozempic under patent and no generic exists. NC Medicare filled 310,812 Ozempic prescriptions in 2023 at $1,311 each. Metformin, used for the same condition by more than twice as many patients, costs about $10 per prescription, so Ozempic costs 131 times more per fill.
Ozempic was picked for the second round of Medicare's price negotiation program under the Inflation Reduction Act. CMS announced a negotiated price of $274 for a 30-day supply of semaglutide, which covers Ozempic, Rybelsus and Wegovy, starting January 1, 2027. The list price CMS compared it with was about $959, so the negotiated price is roughly 71% lower.
That $274 is what Medicare will pay, not a new copay. Your Part D plan still sets your deductible, tier and cost sharing, so your actual savings will not be clear until your plan publishes its 2027 benefits. Read your 2027 Annual Notice of Change to see how your plan will treat Ozempic.
| Diabetes drug | Negotiated price takes effect |
|---|---|
| Jardiance, Farxiga | January 1, 2026 |
| Ozempic, Rybelsus, Wegovy | January 1, 2027 |
| Trulicity | Selected for negotiation in January 2026; any price would take effect no earlier than January 1, 2028 |
Plans place Ozempic on different tiers, and prior authorization is common, so compare your specific plans. Part D caps what you pay out of pocket for covered drugs at $2,100 in 2026 and $2,400 in 2027. Once you reach it you pay $0 for covered Part D drugs for the rest of the year, and the Medicare Prescription Payment Plan can spread costs into monthly payments. Check Ozempic specifically in Medicare Plan Finder, because the yearly cost difference between plans can be large for this one drug.
From July 1, 2026 through December 31, 2027, the CMS Medicare GLP-1 Bridge lets eligible Part D enrollees, in a stand-alone drug plan or a Medicare Advantage plan with drug coverage, get Wegovy (injection and tablets), the KwikPen form of Zepbound and Foundayo for a flat $50 monthly copay. It requires prior authorization from your prescriber, it is processed separately from your Part D plan, and the $50 does not count toward your Part D deductible or out-of-pocket cap. It does not change how Ozempic is covered for diabetes.
Skyler Abilla is a licensed Medicare agent serving North Carolina and South Carolina. Bring your medication list and we will check each drug against every plan available at your address. Call (843) 284-6815 or book a free call. For the bigger 2027 picture, read our guide to Medicare Part D in 2027.
Source: CMS Medicare Part D Prescribers by Geography and Drug, 2023 (North Carolina). Negotiated prices: CMS Medicare Drug Price Negotiation Program, as reported by NBC News (November 2025) and NCPA (December 2025). Third-cycle drug list: CMS press release, January 27, 2026. GLP-1 Bridge: CMS program details as summarized by NFP (June 10, 2026). Part D 2027 cap: CMS CY 2027 Rate Announcement (April 2026).
Tell us a little about you and a licensed Abilla Advisors agent will call you. No cost, no obligation.
We do not offer every plan available in your area. To get information on all of your options, contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Assistance Program (SHIP).
Get personalized Medicare guidance with no cost and no obligation.